Opportunity AssessmentCase Study

Evaluation of the market potential for an asset being developed for a chronic respiratory indication

The Situation

Bluestar was engaged by a pharmaceutical company to evaluate the U.S. market opportunity for an early development stage asset being developed for the treatment of a chronic respiratory condition

The Ask

Client sought an assessment of the patient segmentation, unmet needs, reaction to a target product profile (TPP) and key product attributes, likely adoption of the product, and the evolving competitive landscape
Client wanted an independent revenue forecast as part of the analysis

The Actions

Primary Research

Conducted in-depth interviews with more than 30 physicians across a variety of specialties involved in the management of the disease, including key opinion leaders and academic and community physicians
Interviews provided feedback on patient management, unmet needs, future competitors, the TPP, and potential adoption

Secondary Research

Assessed disease overview and epidemiology, diagnosis, patient segmentation, size of the addressable patient population, patient journey, and treatment paradigm
Provided an overview of the development pipeline

Financial Forecasting

Constructed a revenue forecast with adjustable metrics to understand sensitivities around key variables, including patient segments, market share, price, and treatment response rate

The Impact

Delivered a detailed overview of the disease, patient segmentation, patient flow, competitive landscape, and treatment paradigm

Gained feedback on the TPP across various product attributes and assessed how the product may be adopted across relevant patient segments in the future treatment landscape

Developed a detailed revenue forecast with variable assumption toggles to both evaluate key sensitives and be able to refine the forecast as additional data emerged

Bluestar BioAdvisors, LLC

521 Fifth Avenue, 25th Floor
New York, NY USA 10175

(212) 257-6030